InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,712.69
(
-0.28%
)
US TECH 100
19,431.20
(
-0.34%
)
Dow Jones
41,794.60
(
-0.61%
)
Brent Oil
74.92
(
-0.27%
)
Bitcoin
68,748.68
(
1.37%
)
Post# of 253527
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120665
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: ranjo post# 209345

Thursday, 02/23/2017 9:56:48 AM

Thursday, February 23, 2017 9:56:48 AM

Post# of 253527

…if EXAS can eliminate an invasive biopsy on lung nodules…

That would indeed be a big breakthrough, but it’s a much tougher task than detecting biomarkers for CRC in a stool sample (what Cologuard does).

…all their diagnostics will use the same platform as CG quarts, so no huge capex.

I’m not sure what you mean by quarts—please clarify.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up